Scientists create organoid biobank to study SARS-CoV-2 genes 20 September 2021 | By Anna Begley (Drug Target Review) Researchers have established an organoid biobank to search for genes that are essential for the spreading of SARS-CoV-2 infection.
Ex vivo stem cell treatment a promising therapy against MRSA 17 September 2021 | By Anna Begley (Drug Target Review) A new ex vivo model treated animal wounds with mesenchymal stromal cells (MSCs) and reduced MRSA infection, expanding therapeutic options for humans.
Researchers identify specific drug targets for a variety of brain disorders 17 September 2021 | By Anna Begley (Drug Target Review) Scientists have discovered drug targets in the neural circuits that encode memories, paving the way for the treatment of brain disorders.
MEPs demand action plan to end animal testing in Europe 16 September 2021 | By Anna Begley (Drug Target Review) MEPs have requested that the EU adopts new plans to phase out the use of animals in scientific research and testing, focusing on alternatives instead.
Novel technology could significantly advance genomics field 16 September 2021 | By Anna Begley (Drug Target Review) New technology system of drug-based markers for the selection or counter-selection of genes may advance genetic screening methods.
Scientists reveal that glioblastoma shows dependency on biotin distribution 15 September 2021 | By Anna Begley (Drug Target Review) Researchers discovered that glioblastoma cells rely on biotin distribution for growth, leading to possible future drug combinations.
Gut microbiome linked to rheumatoid arthritis prognosis 15 September 2021 | By Anna Begley (Drug Target Review) New genomic study reveals that the microbiome could predict rheumatoid arthritis prognosis, potentially advancing treatments.
Gene therapy for Morquio A disease successful in rat model 14 September 2021 | By Anna Begley (Drug Target Review) A novel gene therapy has fully corrected whole-body alterations in a rat model, paving the way for Morquio A therapies.
Immune cells found co-operating to capture and “eat” bacteria 13 September 2021 | By Anna Begley (Drug Target Review) Researchers have identified a spider-like antibacterial mechanism by immune cells that could inspire Staphylococcus aureus treatments.
Scientists create cellular blueprint of multiple sclerosis lesions 13 September 2021 | By Anna Begley (Drug Target Review) An NIH team have built a cellular map of chronic multiple sclerosis (MS) lesions to identify cells that drive inflammation and potential therapies.
PP2A enzyme could be major driver of preeclampsia 10 September 2021 | By Anna Begley (Drug Target Review) A new study found that protein phosphatase 2 (PP2A) found to be a major driver of preeclampsia, potentially leading to treatments.
Novel tool can estimate number of T cells in cancer tumours 10 September 2021 | By Anna Begley (Drug Target Review) Researchers have developed a new method that can rapidly count the number of T cells in a tumour, helping to predict patient response to therapies.
New Gut Cell Atlas reveals genetic origins of Crohn’s disease 10 September 2021 | By Anna Begley (Drug Target Review) The Gut Cell Atlas comprises 428,000 cells in the gut and sheds light on the origin of Crohn’s disease and other intestinal diseases.
STING-activating drugs could customise cancer treatments 9 September 2021 | By Anna Begley (Drug Target Review) An imaging technique identified emerging drugs that activate the STING protein to alter metabolic pathway activity in cancer cells.
Artificial intelligence could revolutionise glycomics datasets 9 September 2021 | By Anna Begley (Drug Target Review) Researchers have created a tool that allows glycomics datasets to be analysed using artificial intelligence for early cancer diagnoses.
